Maze Therapeutics Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Employees
  • 120
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $190M
Latest Deal Amount
  • Investors
  • 16

Maze Therapeutics General Information

Description

Developer of a biotechnology platform intended to focus on translating genetic insights into new medicines. The company's platform combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches to reveal modifier genes that confer protection and provide a deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling pharma companies to develop novel therapies.

Contact Information

Website
www.mazetx.com
Formerly Known As
Genetic Modifiers NewCo
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 131 Oyster Point Boulevard
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Maze Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Maze Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 10-Jan-2022 $190M 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 25-Oct-2019 00000 00000 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 28-Feb-2019 $191M $191M 00000 Completed Generating Revenue
To view Maze Therapeutics’s complete valuation and funding history, request access »

Maze Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
Series A 000,000,000 00.000000 00 00 00 00 00.000
To view Maze Therapeutics’s complete cap table history, request access »

Maze Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biotechnology platform intended to focus on translating genetic insights into new medicines. The company'
Biotechnology
South San Francisco, CA
120 As of 2022
00000
0000000000 0 00000

00000000

te irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Exce
0000 000000000
San Carlos, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000

0000000

scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veni
0000 000000000
La Jolla, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Maze Therapeutics Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexigen Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
0000000 Formerly VC-backed La Jolla, CA 000 00000 00000000 00000
00000 Formerly VC-backed Cambridge, MA 000 00000 000000&0
000 00000000000000 Venture Capital-Backed Philadelphia, PA 00 000.00 00000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 35 competitors. Get the full list »

Maze Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Jason Coloma Ph.D Chief Executive Officer, President, Board Member & Chief Mazer
Atul Dandekar Chief Strategy Officer
Allison Richards Director, Financial Planning & Analysis
Tara Nickerson Ph.D Chief Business Officer
Aaron Gitler Ph.D Co-Founder
You’re viewing 5 of 12 executive team members. Get the full list »

Maze Therapeutics Board Members (14)

Name Representing Role Since
Andy Tran Matrix Capital Management Board Member 000 0000
Brendan Bulik-Sullivan Ph.D Self Board Member 000 0000
Catherine Sohn Maze Therapeutics Board Member 000 0000
Charles Homcy MD Self Chairman 000 0000
Daniel Spiegelman Maze Therapeutics Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Maze Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Maze Therapeutics Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Andreessen Horowitz Venture Capital Minority 000 0000 000000 0
Driehaus Capital Management Corporation Minority 000 0000 000000 0
General Catalyst Venture Capital Minority 000 0000 000000 0
Matrix Capital Management Hedge Fund Minority 000 0000 000000 0
Moore Strategic Ventures Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Maze Therapeutics Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 000 07-Dec-2020 00000 0000 Biotechnology 00000 000
Contour Therapeutics 07-Dec-2020 Joint Venture Drug Discovery 00000 000
To view Maze Therapeutics’s complete investments history, request access »

Ready to get started?

Request a free trial